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Introduction: The safety of aprotinin, especially when used with profound
hypothermic circulatory arrest, is still a matter of intense debate despite its
presumed salutary effects on blood loss. Many investigators have reported
toxic renal effects of high-dose aprotinin in such patients, but no prospec-
tive, randomized study has been conducted. To assess the potential
detrimental effect of aprotinin on renal function and its putative reduction
of blood loss, 50 patients undergoing thoracic aortic operations with the use
of profound hypothermic circulatory arrest were randomly assigned to
receive either low-dose aprotinin (1 3 106 kallikrein activation units) or
placebo. Methods: The specific renal tubular markers b-2-microglobulin
and b-N-acetyl-D-glucosaminidase, as well as serum creatinine and blood
urea nitrogen, creatinine clearance, sodium excretion, and potassium
excretion, were measured to evaluate renal function preoperatively, imme-
diately after the procedure, and 24 hours and 48 hours later. Results: No
statistically significant difference was found in any measured renal param-
eter between the two groups (analysis of variance). Renal dysfunction,
defined as an elevation of serum creatinine early postoperatively (>21.5
times the preoperative value), occurred in two patients who received
aprotinin and in one patient in the control group. Temporary dialysis
(hemodialysis or continuous venovenous hemofiltration) was needed in two
patients in the aprotinin group versus one in the control group. Further-
more, patients treated with aprotinin had significantly less total postoper-
ative blood loss (718 6 340 ml vs 920 6 387 ml, p 5 0.04). The aprotinin
recipients also had a significantly lower transfusion requirement (p <0.05).
Conclusion: This controlled trial of low-dose aprotinin in patients under-
going thoracic aortic operations using profound hypothermic circulatory
arrest demonstrated no detectable deleterious effects on renal function;
moreover, the use of aprotinin was associated with significantly lower need
for transfusion. (J Thorac Cardiovasc Surg 1998;115:220-5)
Aprotinin (Trasylol), a serine protease inhibitor,has been widely advocated for preservation of
hemostatic function in cardiopulmonary bypass sur-
gery. Several mechanisms appear to exert a hemo-
static effect, including reduction of fibrinolysis,1
inhibition of neutrophil activation,2 and preserva-
tion of platelet function.3, 4 Furthermore, its molec-
ular weight is low (6500 D) and it is rapidly elimi-
nated (t1⁄2 5 2 hr) from the circulation by
glomerular filtration with a temporary partial stor-
age of the administered dose (80% to 90%) by the
proximal tubular cells.
Aprotinin is now routinely used in many centers
for all cardiac operations, and in this setting few
complications or side effects attributed to its use
have been reported. Aprotinin may be of particular
benefit in high-risk cardiac procedures such as redo
cardiopulmonary bypass (CPB) operations and es-
pecially in patients undergoing complex aortic pro-
cedures in which profound hypothermic circulatory
arrest is used and coagulopathies such as platelet
dysfunction may be expected.
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Some recent clinical studies have shown an in-
creased risk of myocardial infarction, multiorgan
platelet thrombi, and especially renal dysfunction
and failure in patients receiving high-dose aprotinin
(2 3 106 kallikrein inactivation units [KIU] aproti-
nin as a loading dose, 2 3 106 KIU added to the
CPB circuit, and a continuous infusion of 250,000
KIU/hr until conclusion of the operation) during
hypothermic circulatory arrest.5, 6
Therefore the primary objective of this study was
to evaluate the efficacy and safety of low-dose
aprotinin on renal function in patients undergoing
operations on the thoracic aorta under conditions of
profound hypothermia and circulatory arrest com-
pared with a placebo-controlled group. We also
rigorously evaluated postoperative blood loss and
transfusion requirements in both groups of patients.
Patients, materials, and methods
Between July 1995 and July 1996, 50 patients, with
informed consent, underwent resection of different parts
of the aorta at the University Hospital of Vienna. All
patients were randomly assigned to receive either low-
dose aprotinin or placebo. Each group contained 25
patients who had given informed consent. Patients ran-
domized to be in the aprotinin group received 1 3 106
KIU of aprotinin (140 mg) (Trasylol; Bayer AG, Le-
verkusen, Germany) before onset of CPB with the heart-
lung machine. The patients in the control group received
an equal volume of 0.9% saline solution as a placebo.
The preparation for randomization of the study was as
follows: Each bottle of aprotinin provided by the Bayer
Company contained 500,000 KIU. Therefore, 50 bottles
were obtained to provide 1 3 106 KIU of aprotinin for
each of 25 patients. These 50 bottles were placed in a box
with 50 bottles of normal saline solution. These bottles
were indistinguishable from one another. One assistant,
who was only involved in randomization of the medica-
tions, arranged these 100 bottles into 50 pairs. Each pair
consisted of two bottles of aprotinin or two bottles of
saline solution. Each of these pairs was randomly assigned
a number from 1 to 50. Only the aforementioned assistant
was privy to the assignments. Each patient was randomly
assigned a number and then given the corresponding
bottles. After the study was completed, the randomization
code was broken and the data were statistically analyzed.
Patients with a preoperative serum creatinine level ex-
ceeding 2 mg/dl were excluded from this study. Table I
summarizes important demographic and clinical charac-
teristics of both groups. The incidences of hypertension,
smoking history, and coronary artery disease were com-
parable in both groups, whereas the control group had a
higher frequency of diabetes.
Thirty-four patients had chronic type A dissection with
an aortic diameter of greater than 6 cm at the time of
operation. The remaining 16 patients were admitted for
operation because of an atherosclerotic aneurysm with an
aortic diameter enlargement to 6 cm. Aneurysmal disease
was diagnosed by either transesophageal echocardiogra-
phy or computed tomography. All patients were operated
on electively.
Systemic anticoagulation for CPB was obtained accord-
ing to standard protocol by the administration of 3 mg/kg
of intravenous heparin. Activated clotting time (ACT) was
measured during CPB and at onset of circulatory arrest
with a kaolin assay. The amount of heparin administered
and the ACTs achieved are shown in Table II. Urine and
blood samples were taken at the following times: (1)
before the operations, (2) immediately after the opera-
tions, (3) on the first postoperative day, and (4) the second
day postoperatively. The urine samples were taken from a
urinary catheter. All samples were collected and stored at
–20° C before further processing. Homologous packed red
cells were administered postoperatively only when the
hematocrit value fell to less than 25%. The mediastinal
and thoracic blood was collected, and the amount was
measured for the first 24 hours postoperatively.
Statistical methods. Values are presented as mean 6
standard deviation or medians as indicated. Differences
between values were evaluated for statistical significance
by analysis of variance with Statistical Analysis System
software (SAS Institute, Inc., Cary, N.C.).7 A p value less
than 0.05 was considered significant.
Surgical technique. The surgical technique and the
application of profound hypothermic circulatory arrest
throughout the study period were standard. The method
of deep hypothermia and circulatory arrest has been
previously described in detail.8 In brief, it consists of core
cooling during CPB to produce deep hypothermia to a
rectal temperature of 18° C. Operations on the ascending
aorta and proximal arch were performed through median
sternotomy, whereas access for operations on the de-
scending aorta was through a posterolateral incision in the
fourth intercostal space. Depending on the extension of
the pathologic involvement, either the aortic arch or the
ascending or descending aorta was resected and replaced
by a tubular graft (Vascutek, Inchinnan, Scotland). In
Table I. Preoperative patient data
Variable
Aprotinin
(n 5 25)
No aprotinin
(n 5 25)
Age (yr)
Mean 70 70
Range (yr) 58-80 60-78
. 65 yr 7 (28) 5 (20)
Male sex 9 (36) 7 (28)
Hypertension 20 (80) 18 (72)
Diabetes 1 (4) 5 (20)
Smoking history 13 (52) 11 (44)
Coronary artery disease 6 (24) 4 (16)
Previous CABG 2 (8) 3 (12)
Sternotomy 20 (80) 22 (88)
Posterolateral exposure 5 (20) 3 (12)
Dissection 19 (76) 15 (60)
Atherosclerotic 6 (24) 10 (40)
CABG, Coronary artery bypass grafting.
Numbers in parentheses are percentage.
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cases of arch involvement the period of circulatory arrest
was used for inspection and reconstruction of the arch.
Results
Intraoperative parameters. As depicted in Table
III, no differences were found in aortic crossclamp,
extracorporeal circulation, and circulatory arrest
times.
Renal parameters and adverse effects. All com-
plications that occurred in both groups are summa-
rized in Table IV. Renal dysfunction, defined as an
elevation of the serum creatinine level in the first
postoperative week to a level 1.5 times the preop-
erative value or higher, occurred in two patients who
received aprotinin and in one patient in the control
group. The need for temporary postoperative dialy-
sis (hemodialysis or continuous venovenous hemo-
filtration dialysis) was seen in two patients in the
aprotinin group versus one patient in the control
group. None of the 43 surviving patients required
permanent dialysis. No significant difference could
be seen in blood urea nitrogen, creatinine, b-N-
acetyl-D-glucosaminidase (b-NAG) and b-2-micro-
globulin (Table V). Similarly, no statistically signif-
icant difference was noted in creatine clearance or in
the sodium and potassium excretion fraction (Table
VI). No patient in either group had a postoperative
myocardial infarction.
Seven deaths occurred overall in the first 30
postoperative days: three in the aprotinin group and
four in the control group. Causes of death included
multiorgan failure in four patients, sepsis in two
patients, and stroke in one patient.
Transfusion requirements and blood loss. The
number of units of red blood cells that were trans-
fused postoperatively in the two groups are shown in
Table VII. Aprotinin recipients required fewer post-
operative transfusions than the control group (p 5
0.04). The mean chest tube drainage in both groups
for the first 24 hours postoperatively is also shown in
Table VII. Reoperation for bleeding was not re-
quired in either group.
Discussion
In this first prospective, double-blind randomized
study, we examined the influence of a low-dose
aprotinin regimen on kidney function and postoper-
ative blood loss in operations performed under
profound hypothermic circulatory arrest.
Clinical use of aprotinin, a serine protease inhib-
itor with a broad spectrum of activity, has shown a
substantial effect in reducing the need for blood
transfusion.9-11 Its mechanism remains to a certain
degree unclear, but it appears that aprotinin inhibits
Table II. Intraoperative heparin and protamine dosage and activating clotting time for aprotinin-treated and
untreated (control) patients
Parameters Aprotinin (n 5 25) No aprotinin (n 5 25) Diff. 95% C.I. for Diff. p Value
Heparin dosage (mg 6 SD) 207 6 65 196 6 44 11 220.56-42.56 p 5 0.49
Protamine dosage (mg 6 SD) 244 6 62 217 6 56 27 26.59-60.59 p 5 0.11
ACT (sec)
During CPB (mean 6 SD 873 6 278 823 6 301 50 2114.7-214.7 p 5 0.54
Before total circulatory ar-
rest (mean 6 SD)
965 6 257 934 6 212 31 2102.9164.9 p 5 0.64
Diff., Difference; C.I., confidence interval.
Results are expressed as mean 6 standard deviation.
Table III. Intraoperative parameters for aprotinin-
treated and untreated (control) patients
Parameters
Aprotinin
(n 5 25)
No aprotinin
(n 5 25)
CPB time (min)
Mean 6 SD 195.2 6 58 182.6 6 55
Range 103-374 76-276
Total circulatory arrest time (min)
Mean 6 SD 31.4 6 14.2 29.3 6 12.7
Range 14-72 13-75
Aortic crossclamp time (min)
Mean 6 SD 107 6 42 82 6 37
Range 0-229 0-165
CPB, Cardiopulmonary bypass; SD, standard deviation.
Table IV. Complications occurring in patients
undergoing operations under profound hypothermic
circulatory arrest with and without the use of
aprotinin
Complications Aprotinin No aprotinin
Reversible neurologic deficit 1 2
Stroke 0 1
Myocardial infarction 0 1
Renal dysfunction 2 1
Renal failure 2 1
30-day mortality 3 4
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activation of the kallikrein-kinin system12 and plas-
min fibrinolysis system, preserves platelet func-
tion,13 and partially inhibits neutrophil activation
during CPB.2 Aprotinin is now routinely adminis-
tered prophylactically, mostly in the conventional
“Hammersmith” full-dose regimen with consider-
able success, especially in high-risk cardiac proce-
dures, such as redo operations, at a number of
European heart centers. It would seem logical to use
aprotinin in highly complex operation on the tho-
racic aorta in which deep hypothermia and circula-
tory arrest are advocated and coagulopathies may be
expected.
The efficacy and safety of aprotinin during pro-
found hypothermia and circulatory arrest are still
matters of intense debate. Clinical evidence is gain-
ing that under deep hypothermic perfusion aproti-
nin is ineffective and even potentially harmful.5, 6
Because approximately 90% of an administered
dose is known to collect in the brush border of the
convoluted tubules,14 speculation has been raised
that high-dose aprotinin might adversely affect the
kidneys.
Therefore the goal of this study was to investigate
whether the use of low-dose aprotinin (1 million
KIU) would also lead to a higher rate of renal
complications. We explored the question of whether
the reduction in postoperative bleeding could still be
achieved with a reduced dose of aprotinin.
Our study demonstrated that no increase in renal
dysfunction was found in the first 48 hours postop-
eratively. With regard to renal parameters, espe-
cially the very specific markers b-NAG and b-2-
microglobulin that clearly reflect damage to the
proximal tubule cells of the kidney, no significant
difference was seen among the study and the control
groups. Similarly, there was no difference in blood
urea nitrogen, creatinine, creatinine clearance, and
excretion fractions of potassium and sodium. None
of the surviving patients required permanent hemo-
dialysis.
Conversely, Sundt and colleagues5 administered
aprotinin to 20 patients undergoing operations on
the thoracic aorta under conditions of profound
hypothermic circulatory arrest and compared the
results with a well-matched control group. Renal
dysfunction, defined as an elevation of the serum
creatinine level in the first postoperative week to a
level 1.5 times higher than preoperatively, occurred
in 65% of their patients who received aprotinin and
only one patient who did not receive the drug.
Twenty-five percent of their patients who received
aprotinin had undergone renal dialysis. Postmortem
findings on these patients showed major evidence of
platelet-fibrin thrombi formation in the kidneys.
However, Goldstein and colleagues15 recently per-
formed a retrospective study comparing 24 patients
who received high-dose aprotinin and placebo, and
they did not observe any statistical difference in
terms of renal dysfunction or failure comparing both
groups. The findings by Sundt and colleagues might
be because their study was performed at a time
when the distorting effect of aprotinin ACT after
filtration with Celite diatomaceous earth (Celite
Corporation, Quincy, Wash.) was not clearly recog-
nized.16, 17 So far, it is known that aprotinin neutral-
izes the anticoagulating effect of heparin to some
extent, and ACT times should be maintained at
Table V. Comparison of preoperative and postoperative renal parameters in aprotinin-treated and untreated
control patients
Variable
Aprotinin
preoperative
Placebo
preoperative Difference
95% C.I. for
differences
p
Value
Aprotinin
postoperative
Placebo
postoperative Difference
95% C.I. for
differences
p
Value
BUN 21.53 6 2.23 21.12 6 2.02 0.41 20.78-1.6 0.47 23.58 6 2.49 22.32 6 2.47 1.26 20.13-2.65 0.13
Creatinine 0.94 6 0.16 0.86 6 0.16 0.08 20.1-0.17 0.15 0.80 6 0.14 0.89 6 0.18 20.09 20.17-0 0.11
b-NAG 4.44 6 1.60 4.97 6 1.09 20.53 21.3-0.24 0.16 4.99 6 1.51 5.39 6 1.09 20.4 21.14-0.34 0.17
b-2-microglobulin 1.35 6 0.39 1.35 6 0.47 0 20.24-0.24 0.98 1.28 6 0.34 1.29 6 0.33 20.01 20.19-0.17 0.96
Variable
Aprotinin
24 hr
Placebo
24 hr Difference
95% C.I. for
differences
p
Value
Aprotinin
48 hr
Placebo
48 hr Difference
95% C.I. for
differences
p
Value
BUN 30.26 6 22.18 26.4 6 17.10 3.86 27.4-15.12 0.24 31.38 6 21.66 27.47 6 18.76 3.91 27.61-15.43 0.27
Creatinine 1.33 6 1.18 1.09 6 0.80 0.24 20.33-0.81 0.26 1.10 6 0.63 0.98 6 0.70 0.12 20.17-0.41 0.30
b-NAG 5.32 6 1.18 5.40 6 1.00 20.08 20.68-0.52 0.77 5.14 6 1.43 4.74 6 1.05 0.4 20.3-1.10 0.30
b-2-microglobulin 1.29 6 0.31 1.31 6 0.37 20.02 20.2-0.16 0.75 1.25 6 0.45 1.20 6 0.39 0.05 20.18-0.28 0.68
b-NAG, b-N-acetyl-D-glucosominidase; C.I., Confidence interval.
Results are expressed as mean 6 standard deviation.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 1
Ehrlich et al. 2 2 3
greater than 700 seconds.17 It must be emphasized
that in our study ACT was measured in all 50
patients using a kaolin assay, which is essentially
unaffected by aprotinin.18, 19
Blauhut and associates20 investigated renal func-
tion in 26 patients undergoing coronary artery by-
pass grafting with hypothermia to 28° C; half of their
patients received high-dose aprotinin. No difference
in postoperative creatinine clearance was found
between the groups; the osmolar clearance and
potassium and sodium excretion were slightly higher
in the aprotinin-treated patients postoperatively.
We could not find any significant differences be-
tween both groups in our study concerning sodium
and potassium excretion, although both parameters
increased in the first 48 hours compared with base-
line values.
Clinical reports describing aprotinin use in pa-
tients undergoing heart surgery have also raised the
possibility that the drug is associated with an in-
creased risk of thrombotic complications and a
higher incidence of perioperative myocardial infarc-
tion. In a study performed on 80 patients undergo-
ing surgery for acute type A aortic dissections with
and without the perioperative administration of
aprotinin, Westaby and colleagues6 described an
increased incidence of postoperative bleeding com-
plications and thrombosis-related deaths among apro-
tinin recipients. Sundt and colleagues5 reported a 20%
high incidence of perioperative myocardial infarction
in 20 patients who underwent aortic operations with
profound hypothermic circulatory arrest.
We did not note any statistically significant differ-
ence in the incidence of transient or permanent
neurologic deficits, nor did we see an increase of
myocardial infarction in the aprotinin-treated
group. This might be explained primarily by the
low-dose regimen that we administered in our study
and again by the fact that ACT was measured with
the kaolin method.
In summary, it can be said that low-dose aprotinin
can safely and effectively be used in patients under-
going aortic procedures under conditions of pro-
found hypothermic circulatory arrest. Our results
have shown that the administration of low-dose
aprotinin has no deleterious effect on renal function
and does not increase the risk of myocardial infarc-
tion. Most important, low-dose aprotinin effectively
reduces blood loss and red blood cell transfusion
requirements.
Table VII. Blood component transfusions and postoperative blood loss
Variable Aprotinin No aprotinin p Value
Postoperative exogeneous packed erythrocyte transfusion requirements (units) 1.2 6 0.4 3.5 6 0.6 p 5 0.0001
Other products* transfused after operation (units) 2.4 6 1.04 5.08 6 1.7 p 5 0.0001
Chest tube output (ml) first 24 hours 717 6 340 920 6 387 p 5 0.04
Results are expressed as mean 6 standard error.
*Includes platelets, fresh-frozen plasma, and cryoprecipitate.
Table VI. Comparison of preoperative and postoperative creatine clearance, fractional potassium excretion
(normally between 7% and 8%), and fractional sodium clearance (normally ,1%) in aprotinin-treated and
untreated control patients
Variable
Aprotinin
preoperative
Placebo
preoperative Difference
95% C.I. for
differences
p
Value
Aprotinin
postoperative
Placebo
postoperative Difference
95% C.I. for
differences
p
Value
Creatinine clearance 92.3 6 3.53 90.9 6 4.43 1.4 20.9-3.7 0.23 134.7 6 5.49 133.7 6 3.32 1 21.57-3.57 0.45
Potassium excretion 8.72 6 0.11 8.65 6 0.16 0.07 0-0.14 0.06 9.34 6 0.04 9.30 6 0.09 0.04 0-0.43 0.06
Sodium excretion 1.65 6 0.07 1.69 6 0.09 20.04 20.08-0 0.09 2.65 6 0.15 2.59 6 0.15 0.06 20.02-0.14 0.28
Variable
Aprotinin
24 hr
Placebo
24 hr Difference
95% C.I. for
differences
p
Value
Aprotinin
48 hr
Placebo
48 hr Difference
95% C.I. for
differences
p
Value
Creatinine clearance 127.5 6 3.01 126.2 6 4.44 1.3 20.85-3.45 0.26 89.6 6 2.12 88.8 6 5.08 0.8 21.4-3 0.42
Potassium clearance 9.54 6 0.11 9.47 6 0.19 0.07 20.01-0.15 0.13 7.89 6 0.05 7.94 6 0.16 20.05 20.11-0.01 0.11
Sodium clearance 1.76 6 0.10 1.72 6 0.14 0.04 20.02-0.1 0.09 1.23 6 0.09 1.17 6 0.14 0.06 0-0.12 0.05
C.I., Confidence interval.
Results are expressed as mean 6 standard deviation.
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